Cost-effectiveness of current and optimal treatment for adult asthma

Internal Medicine Journal
Leonardo SimonellaGavin Andrews

Abstract

This article is part of a project to determine the cost-effectiveness of averting the burden of disease. We used population data to investigate the costs and benefits of allocating resources to optimal treatment for asthma in adults, using a burden of disease framework. We calculated the population burden of asthma in the absence of any treatment as years lived with disability (YLD), ignoring the years of life lost. We then estimated the proportion of burden averted with current interventions, the proportion that could be averted with optimally implemented current evidence-based guidelines and the direct treatment cost-effectiveness ratio in dollarA per YLD averted for both current and optimal treatment. The direct treatment cost of current treatment of adult asthma in Australia was dollar A452 million and averted 25% of the burden with a cost-effectiveness ratio of dollar A14 000/YLD averted. Optimal treatment and optimal compliance would cost dollar A627 million and avert 69% of the burden with a cost-effectiveness ratio of dollar A7000/YLD averted. Implementation of optimal treatment for asthma is affordable, will be more cost-effective and will significantly decrease disability.

References

Jan 1, 1995·International Journal of Technology Assessment in Health Care
Apr 1, 1994·Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation·M E HylandP A Jacobs
Jan 16, 1999·Australian and New Zealand Journal of Public Health·S M Lister, L R Jorm
May 3, 2000·Health Economics·C J MurrayR M Baltussen
Feb 7, 2001·The British Journal of Psychiatry : the Journal of Mental Science·G AndrewsW Hall
Aug 21, 2001·The European Respiratory Journal·E F JuniperJ N Roberts
Dec 4, 2001·Bulletin of the World Health Organization·C D MathersS J Begg
Jul 10, 2002·New South Wales Public Health Bulletin·Louisa Jorm
Sep 25, 2002·Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology·Ricardo A Tan, Sheldon L Spector
Aug 21, 2003·Medical Decision Making : an International Journal of the Society for Medical Decision Making·Todd A LeeSean D Sullivan
Dec 6, 2003·The Journal of Allergy and Clinical Immunology·Sean D SullivanKevin B Weiss
Jun 3, 2004·The British Journal of Psychiatry : the Journal of Mental Science·Gavin AndrewsHelen Lapsley
Oct 12, 2004·Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation·Kristy SandersonHelen Lapsley

❮ Previous
Next ❯

Citations

Jul 27, 2006·The Australian and New Zealand Journal of Psychiatry·Gavin Andrews
Sep 9, 2006·The Australian and New Zealand Journal of Psychiatry·Gavin Andrews
Sep 18, 2007·International Journal of Clinical Practice·L WatsonK F Rabe
Nov 3, 2010·International Journal of Chronic Obstructive Pulmonary Disease·Davood AttaranReza Basiri
Jun 5, 2013·Australian and New Zealand Journal of Public Health·Vittal Mogasale, Theo Vos
Nov 3, 2009·Osteoarthritis and Cartilage·J A KopecE M Badley
Jan 22, 2019·Journal of Medical Economics·Bunchai ChongmelaxmePiyameth Dilokthornsakul
Oct 29, 2008·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Philip M PolgreenForrest D Nelson
Oct 6, 2007·Wiener medizinische Wochenschrift·Viktoria SteinAnita Rieder

❮ Previous
Next ❯

Related Concepts

Related Feeds

Asthma

This feed focuses in Asthma in which your airways narrow and swell. This can make breathing difficult and trigger coughing, wheezing and shortness of breath.

Allergy and Asthma

Allergy and asthma are inflammatory disorders that are triggered by the activation of an allergen-specific regulatory t cell. These t cells become activated when allergens are recognized by allergen-presenting cells. Here is the latest research on allergy and asthma.

Related Papers

BMJ : British Medical Journal
Richard Layard
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology
Hans-Ulrich Wittchen, Frank Jacobi
Lancet
Gavin Andrews, Nickolai Titov
© 2022 Meta ULC. All rights reserved